tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Infection D007239 6 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Tachycardia D013610 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Metaplasia D008679 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Chronic Disease D002908 7 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Sinusitis D012852 9 associated lipids
Cicatrix D002921 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Leukocytosis D007964 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Glycosuria D006029 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Haas M et al. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. 1999 Am. J. Kidney Dis. pmid:10401019
Gold BG et al. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. 1999 Neurosci. Lett. pmid:10400242
Magee CC et al. Immunosuppressive agents in organ transplantation. 1999 Hosp Med pmid:10396414
Kochi S et al. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. 1999 Eur. J. Pharmacol. pmid:10395024
Horowitz MM et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. 1999 Biol. Blood Marrow Transplant. pmid:10392964
Hasselder AS The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. 1998 Apr-Jun EDTNA ERCA J pmid:10392057
Liang H et al. Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. 1999 J. Biol. Chem. pmid:10391929
Gerhardt U et al. Blood pressure control in kidney transplant recipients: influence of immunosuppression. 1999 J Auton Pharmacol pmid:10385269
Squadrito F et al. Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. 1999 Br. J. Pharmacol. pmid:10385251
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Koski GK et al. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. 1999 J. Immunol. pmid:10384103
Henry ML Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. 1999 Clin Transplant pmid:10383101
Higgins RM et al. Conversion between cyclosporin and tacrolimus--30-fold dose prediction. 1999 Nephrol. Dial. Transplant. pmid:10383044
Cox KL et al. Paediatric liver transplantation: indications, timing and medical complications. 1999 J. Gastroenterol. Hepatol. pmid:10382641
Lieberman DN and Mody I Properties of single NMDA receptor channels in human dentate gyrus granule cells. 1999 J. Physiol. (Lond.) pmid:10373689
Kirk AD et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 1999 Nat. Med. pmid:10371508
Matzinger P Graft tolerance: a duel of two signals. 1999 Nat. Med. pmid:10371494
Przepiorka D et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. 1999 Biol. Blood Marrow Transplant. pmid:10371361
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Onsager DR et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. 1999 J. Heart Lung Transplant. pmid:10363689
Venz S et al. Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. 1999 Transpl. Int. pmid:10363595
Jiang H et al. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival. 1999 Transpl. Int. pmid:10363590
Kanoh S et al. Effect of FK506 on ATP-induced intracellular calcium oscillations in cow tracheal epithelium. 1999 Am. J. Physiol. pmid:10362712
Gummert JF et al. Newer immunosuppressive drugs: a review. 1999 J. Am. Soc. Nephrol. pmid:10361877
Johnson KL and Lawen A Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. 1999 Immunol. Cell Biol. pmid:10361256
Doolabh VB and Mackinnon SE FK506 accelerates functional recovery following nerve grafting in a rat model. 1999 Plast. Reconstr. Surg. pmid:10359255
Cao S et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. 1999 Pediatr Transplant pmid:10359027
Cheng HH et al. Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase. 1999 J. Biol. Chem. pmid:10358074
Muramatsu K et al. Limb allotransplantation in rats: combined immunosuppression by FK-506 and 15-deoxyspergualin. 1999 J Hand Surg Am pmid:10357540
Toung TJ et al. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. 1999 Stroke pmid:10356112
Yang J et al. Sjögren's syndrome in mice carrying the Ipr(cg) gene and the therapeutic efficacy of an immunosuppressive agent FK506. 1999 Pathol. Int. pmid:10355966
Zarifian A et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. 1999 Kidney Int. pmid:10354295
Murata M et al. A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. 1999 Br. J. Haematol. pmid:10354150
Möller A et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. 1999 Drug Metab. Dispos. pmid:10348790
Araki T et al. Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation. 1999 Metab Brain Dis pmid:10348311
Oddis CV et al. Tacrolimus in refractory polymyositis with interstitial lung disease. 1999 Lancet pmid:10347992
Siemann G et al. Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. 1999 Mol. Pharmacol. pmid:10347253
Boehringer M et al. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin. 1999 Nephrol. Dial. Transplant. pmid:10344407
Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin. 1998 Prescrire Int pmid:10342948
Dresske B et al. WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. 1998 Transpl. Immunol. pmid:10342738
Khanna A et al. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. 1998 Transpl. Immunol. pmid:10342736
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Uchio E et al. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. 1999 Mar-Apr Clin. Exp. Rheumatol. pmid:10342043
Ruddy SB et al. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. 1999 Int J Pharm pmid:10341307
Ma D and Carlow CK Molecular characterization of FKBP13 from filarial parasites. 1999 Mol. Biochem. Parasitol. pmid:10340490
Conboy IM et al. Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10339586
Ferrand-Drake M et al. Mitochondrial permeability transition induced DNA-fragmentation in the rat hippocampus following hypoglycemia. 1999 Neuroscience pmid:10338300
Steg RE et al. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. 1999 Bone Marrow Transplant. pmid:10338054
Gold BG et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. 1999 J. Pharmacol. Exp. Ther. pmid:10336507
Shirbacheh MV et al. Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. 1999 J. Pharmacol. Exp. Ther. pmid:10336506